Foamix Pharmaceuticals (Foamix Pharmaceuticals) Sale Of Investment : $87.85 Mil (TTM As of Dec. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Foamix Pharmaceuticals Sale Of Investment?

Foamix Pharmaceuticals's sale of investment for the three months ended in Dec. 2019 was $3.18 Mil. It means Foamix Pharmaceuticals gained $3.18 Mil from selling investments. Foamix Pharmaceuticals's sale of investment for the trailing twelve months (TTM) ended in Dec. 2019 was $87.85 Mil.

Compared with last quarter ($27.66 Mil in Sep. 2019 ), Foamix Pharmaceuticals gained less money from selling investments in Dec. 2019 ($3.18 Mil).

Foamix Pharmaceuticals Sale Of Investment Historical Data

The historical data trend for Foamix Pharmaceuticals's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foamix Pharmaceuticals Sale Of Investment Chart

Foamix Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Sale Of Investment

Get a 7-Day Free Trial

22.50

40.11

79.08

66.45

87.85

Foamix Pharmaceuticals Quarterly Data
	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
Sale Of Investment	Get a 7-Day Free Trial															0.20	15.88	41.14	27.66	3.18

Foamix Pharmaceuticals Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $87.85 Mil.

Foamix Pharmaceuticals Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Foamix Pharmaceuticals's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Foamix Pharmaceuticals (Foamix Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foamix Pharmaceuticals Ltd (NAS:FOMX) » Definitions » Sale Of Investment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Holzman Street, Weizmann Science Park, Rehovot, ISR, 7670402

Website

https://www.foamix.com

Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with various pharmaceutical companies. It has The development and commercialization of foam based formulations segment.

Executives

Ilan Hadar	officer: CFO & Country Manager	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Stanley Hirsch	director	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Aharon Schwartz	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Anna Kazanchyan	director	933 MAMARONECK AVENUE, SUITE 103, MAMARONECK NY 10543
Anthony D Bruno	director	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Stern	director	C/O THCG, INC, 650 MADISON AVENUE, 21ST FL, NEW YORK NY 10022
Rex Bright	director	5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart	officer: Chief Scientific Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski	director, officer: CEO	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Mutya Harsch	officer: CLO and General Counsel	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley	officer: Chief Commercial Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003